Posts Tagged ‘anti-obesity medicines’

The docket is open for you to lend your support until January 27. The Center for Medicare and Medicaid Services (CMS) is proposing to open up access to obesity medicines in both of the programs they oversee. This is something that we – with virtually every advocate for obesity care – have been seeking for […]

Will savings from reduced food and beverage spending be sufficient to cover the cost of obesity medicines? Will these medicines transform the patterns of a whole range of consumer purchases? Speculation about GLP-1s, consumers, and economics is rampant right now. It’s popping up in both serious economic reporting and academic journals. The speculation is only […]

A profound shift in the understanding of medicines that help with excessive or abnormal fat is underway. A few years ago, everybody thought of these in only one frame of reference – weight loss drugs. But that is changing now. Discourse about them is moving from weight loss to obesity treatment and even further, to […]

This is a striking change. Until now, the steadfast refusal of CMS to allow coverage of any obesity medicine by Medicare has been unwavering. Then two weeks ago, FDA granted a new indication for semaglutide for persons with both heart disease and obesity to prevent heart attacks, strokes, and deaths. Now CMS says it’s A-OK […]

Hear that rumble? Nope, it not the latest SpaceX launch. It is the roar of growing demand for obesity care in the U.S. Two pieces of news in the last week remind us of how steep the upward line of growth in obesity treatment is right now. To help it scale up their reach to […]

The drug development pipeline is filling up with new new drugs for weight loss or obesity. On Thursday, Novo Nordisk caused the hearts of investors to flutter when it presented topline results on an oral medicine that might be more effective than semaglutide. The value of the company’s stock jumped by 13%. Just a week […]

Obesity Care Week this year comes at a time when we have shiny new tools for treating obesity that are garnering a whole lot of attention. One would have be living under a rock not to have heard all the buzz about semaglutide, tirzepatide, and a host of other medicines coming soon for obesity. But […]

In a new cohort study, it is plain to see that, even before the advent of new GLP-1 medicines for obesity, primary care patients could get better health from obesity care. But health systems hindering delivery of obesity care make this exceedingly unlikely for most people living this disease. A Large Cohort Study from an […]

This sounds like a godsend. “Weight loss jabs could be a more effective and cheaper treatment for drug addiction than rehab, a study suggests.” So says the Telegraph of London. The “weight loss jabs” they’re talking about are liraglutide 3 mg daily injections, also known by the brand name of Saxenda. Sad to say, they […]

Are patent thickets boosting the prices of obesity medicine prices and putting these important medical advances out of reach for everyone but the wealthy and well insured? A new paper in JAMA this week suggests this is true – at least in part. Rasha Alhiary and colleagues explain: “Manufacturers have secured long periods of market […]